James Fox, MD
Interventional Pain Medicine · Knoxville, TNNPI 1952393688
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 33.0% of the total. Reporting peaked in 2019 at $957 and has fallen 76.4% since, to $226 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in TN, where the typical reported total is $5,250.
Across 147 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$950
- Nevro Corp.$460
- Daiichi Sankyo Inc.$306
- Pfizer$152
- Scilex Pharmaceuticals Inc.$148
- Redhill Biopharma Inc.$141
- plus $718 from 20 others
What the payments were for
- Food & beverage$2,875100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 67 | $950 |
| Nevro Corp. | 6 | $460 |
| Daiichi Sankyo Inc. | 14 | $306 |
| Pfizer | 12 | $152 |
| Scilex Pharmaceuticals Inc. | 8 | $148 |
| Redhill Biopharma Inc. | 10 | $141 |
| Almatica Pharma LLC | 8 | $121 |
| Amgen | 1 | $116 |
| Tonix Medicines, Inc. | 1 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Boston Scientific | 1 | $59 |
| Globus Medical | 1 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Vertex | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| GRT US Holding, Inc. | 1 | $18 |
| Avanos Medical | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Abbott | 1 | $14 |
| Fidia Pharma USA Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Shionogi Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$261
- Omnia$134
- Morphabond ER$124
- AIMOVIG$116
How this compares
$2,875 in reported general payments places this provider in the 35th percentile of 41 interventional pain medicine providers in Tennessee.
See all interventional pain medicine providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 190 | $145,969 |
| Diclofenac Potassium | 11 | $117,385 |
| Oxymorphone Hcl ErOxymorphone Hcl | 47 | $28,168 |
| Fentanyl | 183 | $21,816 |
| OxycontinOxycodone Hcl | 26 | $19,111 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 486 | $17,900 |
| Oxycodone Hcl | 867 | $17,758 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 432 | $16,443 |
| Morphine Sulfate ErMorphine Sulfate | 415 | $13,173 |
| Gabapentin | 547 | $7,716 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $3,367 |
| Morphine Sulfate | 93 | $3,071 |
| Pregabalin | 108 | $1,984 |
| Methadone Hcl | 41 | $708 |
| Tramadol Hcl | 34 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $950 | $145,969190 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $19 | $3,07193 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 41 interventional pain medicine providers in Tennessee.
Other interventional pain medicine in Knoxville
- Adolfo CuadraKnoxville$15K
- Donald JonesKnoxville$5K
- William NewtonWinchester$225K
- Ryan BearerWinchester$35K
- Michael WilkinsonJohnson City$35K
- Jacob MillsMountain Home$24K
- Matthew KangasMemphis$22K
- Matthew RupertFranklin$17K
- Cameron ShawverJohnson City$15K
- Christine LeslieMorristown$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.